AC
NGM

AXQ Capital’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

AXQ Capital’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,831
Closed -$44.2K – 632
2023
Q1 		$44.2K Buy
+10,831
New +$50.1K 0.02% 465

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

AXQ Capital's NGM Position: Q2 2023 in Review

AXQ Capital sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2023, closing a stake of 10,831 shares — an estimated $44.2K sold.

AXQ Capital first reported a position in NGM in Q1 2023 and held it in 1 quarter. The position peaked at $44.2K in Q1 2023. 106 funds tracked by Wall St. Rank hold NGM as of Q2 2023.

  • AXQ Capital reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • AXQ Capital sold 10,831 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $44.2K.
  • AXQ Capital first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • AXQ Capital's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $44.2K in Q1 2023.
  • 106 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on AXQ Capital's 13F filing for Q2 2023, filed 11 Aug 2023.